Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 10:12:815900.
doi: 10.3389/fonc.2022.815900. eCollection 2022.

Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas

Zhichao Tian  1 , Weitao Yao  1
Affiliations
Review

Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas

Zhichao Tian et al. Front Oncol. .

Abstract

Taxanes (paclitaxel and docetaxel) play an important role in the treatment of advanced sarcomas. Albumin-bound paclitaxel (nab-paclitaxel) is a new kind of taxane and has many advantages compared with paclitaxel and docetaxel. Nab-paclitaxel is currently approved for the treatment of advanced breast, non-small cell lung, and pancreatic cancers. However, the efficacy of nab-paclitaxel in sarcomas has not been reviewed. In this review, we first compare the similarities and differences among nab-paclitaxel, paclitaxel, and docetaxel and then summarize the efficacy of nab-paclitaxel against various non-sarcoma malignancies based on clinical trials with reported results. The efficacy and clinical research progress on nab-paclitaxel in sarcomas are also summarized. This review will serve as a good reference for the application of nab-paclitaxel in clinical sarcoma treatment studies and the design of clinical trials.

Keywords: albumin-bound paclitaxel; breast cancer; lung cancer; pancreatic cancer; sarcoma; taxanes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Four directions for clinical studies on albumin-bound paclitaxel (nab-paclitaxel) in sarcomas.
See this image and copyright information in PMC

References

    1. von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Ganjoo KN, et al. Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2018) 16:536–63. doi: 10.6004/jnccn.2018.0025 - DOI - PubMed
    1. Sarcoma Committee of Chinese Anti-Cancer Association. Chinese Society of Clinical Oncology . Chinese Expert Consensus on Diagnosis and Treatment of Soft Tissue Sarcomas (Version 2015). Zhonghua Zhong Liu Za Zhi (2016) 38:310–20. doi: 10.3760/cma.j. issn.0253-3766.2016.04.013. - DOI - PubMed
    1. Cipriano CA, Jang E, Tyler W. Sarcoma Surveillance: A Review of Current Evidence and Guidelines. J Am Acad Orthop Surg (2020) 28:145–56. doi: 10.5435/JAAOS-D-19-00002 - DOI - PubMed
    1. Osasan S, Zhang M, Shen F, Paul PJ, Persad S, Sergi C. Osteogenic Sarcoma: A 21st Century Review. Anticancer Res (2016) 36:4391–8. doi: 10.21873/anticanres.10982 - DOI - PubMed
    1. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol (2010) 21:320–5. doi: 10.1093/annonc/mdq276 - DOI - PubMed

LinkOut - more resources